Picard Medical publishes investor presentation; expects FDA approval for fully implantable TAH by 2028

Picard Medical, Inc.

Over 2,100 STAH implants across 27 countries; only FDA-approved total artificial heart.
Mid-term catalysts: updated BTC label (2Q26), MDR CE-mark (4Q26), NMPA approval (4Q26).
Next-gen fully implantable TAH (Emperor) may seek FDA approval in 2028; patented.
U.S. reimbursement under DRG001 (mean ~$297k); market cap ~$123M as of Jan 11, 2026.
CEO Patrick Schnegelsberg leads team; stock traded $1.63-$13.68 since Aug 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.